Resistance mutation info of drug
Drug General Information | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug ID | D04RLX | ||||||||||
Drug Name | Tariquidar | ||||||||||
Synonyms | Tariquidarth; XR 9576; XR9576; Tariquidar (USAN/INN); N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide; N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide | ||||||||||
Drug Type | Small molecular drug | ||||||||||
Company | Xenova Group Ltd. | ||||||||||
Structure | |||||||||||
Drug Resistance Mutations | |||||||||||
Target Name | Heat shock protein HSP 90-alpha (HSP90AA1) | Target Info | |||||||||
Gene Name | HSP90AA1 | ||||||||||
Uniprot ID | HS90A_HUMAN | ||||||||||
Species | Homo sapiens | ||||||||||
Reference Sequence |
MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIR YESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFME ALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPM GRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEKED KEEEKEKEEKESEDKPEIEDVGSDEEEEKKDGDKKKKKKIKEKYIDQEELNKTKPIWTRN PDDITNEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFVPRRAPFDLFENRKKKNN IKLYVRRVFIMDNCEELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNLVKKC LELFTELAEDKENYKKFYEQFSKNIKLGIHEDSQNRKKLSELLRYYTSASGDEMVSLKDY CTRMKENQKHIYYITGETKDQVANSAFVERLRKHGLEVIYMIEPIDEYCVQQLKEFEGKT LVSVTKEGLELPEDEEEKKKQEEKKTKFENLCKIMKDILEKKVEKVVVSNRLVTSPCCIV TSTYGWTANMERIMKAQALRDNSTMGYMAAKKHLEINPDHSIIETLRQKAEADKNDKSVK DLVILLYETALLSSGFSLEDPQTHANRIYRMIKLGLGIDEDDPTADDTSAAVTEEMPPLE GDDDTSRMEEVD [Homo sapiens] |
||||||||||
Targeted Disease | Breast cancer | ||||||||||
Drug Resistance Mutations |
|
||||||||||
References | |||||||||||
REF 1 | Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. Oncotarget. 2017 Jan 31;8(5):7678-7690. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.